IP Library Granted Patent US 12,419,958
Granted Patent B2
US 12,419,958 · App. 18/606,927 · Granted Sep 23, 2025

Clinical formulations

Inventors: Roger Gay (Acton, MA); Judson Ratliff (Harvard, MA); Romma E. Southwick (Waban, MA)
Assignee: Astellas Institute for Regenerative Medicine
A61K47/26A61K9/08A61K31/7004A61K31/728A61K33/06A61K33/14A61K35/28A61K35/30A61K47/02A61K47/12A61K47/36A61P27/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,419,958
App. No.
18/606,927
Granted
Sep 23, 2025
Kind
B2
Abstract

Some aspects of this disclosure provide clinical media that support viability, re-plating efficiency, and repopulation capacity of cells and tissues during storage for up to 48 hours or longer. The clinical media provided herein are also useful for clinical irrigation. Cell or tissue preparations comprising a cell population or tissue and a clinical medium as provided herein are also provided, as are methods for generating such preparations. Methods for using the clinical media and cell and tissue preparations provided herein, for example, for administering an effective amount of cells or tissue to a subject in need thereof, are also disclosed.

Claims (40)

1. A solution for cell reconstitution, storage, transport and/or administration to a subject comprising

(a) a buffer, maintaining the solution at a physiological pH, optionally wherein the buffer is an acetate buffer and/or a citrate buffer;

(b) 13-19 mM glucose;

(c) 1-2.5 mM KCl;

(d) an osmotically active agent maintaining the solution at a physiological osmolarity; and

(e) a source of divalent cations, comprising a calcium source and a magnesium source,

wherein the solution does not comprise a carbonate buffer or a zwitterionic organic buffer, and further does not comprise glutathione or glutathione disulfide.

2. The solution of claim 1 , wherein the glucose is present at a concentration of 15-17 mM.

3. The solution of claim 1 , wherein glucose is dextrose.

4. The solution of claim 1 , wherein the solution further comprises potassium chloride at a concentration of 1.6-2.4 mM KCl.

5. The solution of claim 1 , wherein the solution is heat sterilized.

6. The solution of claim 1 , further comprising cells.

7. A preparation comprising a solution for cell reconstitution, storage, transport and/or administration to a subject and retinal pigment epithelial (RPE) cells, the solution comprising

(a) a buffer, maintaining the solution at a physiological pH, optionally wherein the buffer is an acetate buffer and/or a citrate buffer;

(b) 13-19 mM glucose;

(c) an osmotically active agent maintaining the solution at a physiological osmolarity; and

(d) a source of divalent cations, comprising a calcium source and a magnesium source, wherein the solution does not comprise a carbonate buffer or a zwitterionic organic buffer, and further does not comprise glutathione or glutathione disulfide.

8. A preparation comprising a solution for cell reconstitution, storage, transport and/or administration to a subject and photoreceptor cells, the solution comprising

(a) a buffer, maintaining the solution at a physiological pH, optionally wherein the buffer is an acetate buffer and/or a citrate buffer;

(b) 13-19 mM glucose;

(c) an osmotically active agent maintaining the solution at a physiological osmolarity; and

(d) a source of divalent cations, comprising a calcium source and a magnesium source, wherein the solution does not comprise a carbonate buffer or a zwitterionic organic buffer, and further does not comprise glutathione or glutathione disulfide.

9. A preparation comprising a solution for cell reconstitution, storage, transport and/or administration to a subject and mesenchymal cells, the solution comprising

(a) a buffer, maintaining the solution at a physiological pH, optionally wherein the buffer is an acetate buffer and/or a citrate buffer;

(b) 13-19 mM glucose;

(c) an osmotically active agent maintaining the solution at a physiological osmolarity; and

(d) a source of divalent cations, comprising a calcium source and a magnesium source, wherein the solution does not comprise a carbonate buffer or a zwitterionic organic buffer, and further does not comprise glutathione or glutathione disulfide.

10. A solution for cell reconstitution, storage, transport and/or administration to a subject comprising calcium chloride, magnesium chloride, sodium citrate, sodium chloride, glucose, potassium chloride, and a viscoelastic polymer in an aqueous solution,

wherein the glucose is present at a concentration of 13-19 mM,

wherein the potassium chloride is present at a concentration of 1-2.5 mM KCl,

wherein the solution does not comprise a carbonate buffer or a zwitterionic organic buffer, and further does not comprise glutathione or glutathione disulfide.

11. The solution of claim 10 , wherein the glucose is present at a concentration of 15-17 mM.

12. The solution of claim 10 , wherein glucose is dextrose.

13. The solution of claim 10 , wherein the solution comprises potassium chloride at a concentration of 1.6-2.4 mM KCl.

14. The solution of claim 10 , wherein the solution is heat sterilized.

15. The solution of claim 10 , further comprising cells.

16. A preparation comprising the solution of claim 10 and retinal pigment epithelial (RPE) cells.

17. A preparation comprising the solution of claim 10 and photoreceptor cells.

18. A preparation comprising a solution for cell reconstitution, storage, transport and/or administration to a subject and mesenchymal cells, the solution comprising calcium chloride, magnesium chloride, sodium citrate, sodium chloride, glucose, potassium chloride, and a viscoelastic polymer in an aqueous solution,

wherein the solution does not comprise a carbonate buffer or a zwitterionic organic buffer, and further does not comprise glutathione or glutathione disulfide.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 19, 2024
From: GAY, ROGER; RATLIFF, JUDSON; SOUTHWICK, ROMMA E.
To: ASTELLAS INSTITUTE FOR REGENERATIVE MEDICINE
Reel/Frame 068630/0874 →
Continuity (4)
Division 17210448 · Mar 23, 2021
Division 15753232
Provisional Application 62206821 · Aug 18, 2015
Related Publication 20240350639A1 · Oct 24, 2024
References Cited (113)
US 5654266A · Chen et al. · 1997 [cited by applicant]
US 6399110B1 · Kikuchi et al. · 2002 [cited by applicant]
US 7736896B2 · Klimanskaya et al. · 2010 [cited by applicant]
US 7794704B2 · Klimanskaya · 2010 [cited by applicant]
US 7795025B2 · Klimanskaya · 2010 [cited by applicant]
US 8268303B2 · Klimanskaya · 2012 [cited by applicant]
US 8961956B2 · Kimbrel et al. · 2015 [cited by applicant]
US 8962321B2 · Kimbrel et al. · 2015 [cited by applicant]
US 9029146B2 · Lim et al. · 2015 [cited by applicant]
US 9040038B2 · Klimanskaya et al. · 2015 [cited by applicant]
US 9040039B2 · Klimanskaya et al. · 2015 [cited by applicant]
US 9040770B2 · Klimanskaya et al. · 2015 [cited by applicant]
US 9045732B2 · Klimanskaya et al. · 2015 [cited by applicant]
US 9080150B2 · Klimanskaya et al. · 2015 [cited by applicant]
US 9181524B2 · Klimanskaya et al. · 2015 [cited by applicant]
US 9193950B2 · Klimanskaya et al. · 2015 [cited by applicant]
US 9562217B2 · Klimanskaya et al. · 2017 [cited by applicant]
US 9649340B2 · Klimanskaya et al. · 2017 [cited by applicant]
US 9650607B2 · Klimanskaya et al. · 2017 [cited by applicant]
US 9730962B2 · Klimanskaya et al. · 2017 [cited by applicant]
US 9752118B2 · McCabe et al. · 2017 [cited by applicant]
US 9763984B2 · Feng et al. · 2017 [cited by applicant]
US 9993503B2 · Feng et al. · 2018 [cited by applicant]
US 10077424B2 · Malcuit et al. · 2018 [cited by applicant]
US 10307444B2 · Lanza et al. · 2019 [cited by applicant]
US 10426799B2 · Feng et al. · 2019 [cited by applicant]
US 10485829B2 · Malcuit et al. · 2019 [cited by applicant]
US 11013808B2 · Gay et al. · 2021 [cited by applicant]
US 11241460B2 · Lanza et al. · 2022 [cited by applicant]
US 11400118B2 · Feng et al. · 2022 [cited by applicant]
US 11957754B2 · Gay et al. · 2024 [cited by applicant]
US 12049642B2 · McCabe et al. · 2024 [cited by applicant]
US 12076347B2 · Feng et al. · 2024 [cited by applicant]
US 12097223B2 · Kimbrel et al. · 2024 [cited by applicant]
US 12109239B2 · Feng et al. · 2024 [cited by applicant]
US 20030216431A1 · Raut · 2003 [cited by applicant]
US 20110274662A1 · Malcuit et al. · 2011 [cited by applicant]
US 20130195806A1 · Gay et al. · 2013 [cited by applicant]
US 20130302824A1 · Klimanskaya et al. · 2013 [cited by applicant]
US 20150272994A1 · Kimbrel et al. · 2015 [cited by applicant]
US 20150366915A1 · Gay et al. · 2015 [cited by applicant]
US 20160030490A1 · Lanza et al. · 2016 [cited by applicant]
US 20160038543A1 · Kimbrel et al. · 2016 [cited by applicant]
US 20160175361A1 · Lanza et al. · 2016 [cited by applicant]
US 20160175362A1 · Lanza et al. · 2016 [cited by applicant]
US 20170252374A1 · Kimbrel et al. · 2017 [cited by applicant]
US 20170274019A1 · Lu et al. · 2017 [cited by applicant]
US 20180008640A1 · Feng et al. · 2018 [cited by applicant]
US 20180023052A1 · Klimanskaya et al. · 2018 [cited by applicant]
US 20180052150A1 · Klimanskaya et al. · 2018 [cited by applicant]
US 20180064761A1 · Klimanskaya et al. · 2018 [cited by applicant]
US 20180072989A1 · McCabe et al. · 2018 [cited by applicant]
US 20180318353A1 · Feng et al. · 2018 [cited by applicant]
US 20190060370A1 · Lanza et al. · 2019 [cited by applicant]
US 20190062703A1 · Malcuit et al. · 2019 [cited by applicant]
US 20190175656A1 · Kimbrel et al. · 2019 [cited by applicant]
US 20190282622A1 · Klimanskaya et al. · 2019 [cited by applicant]
US 20190290701A1 · Lanza et al. · 2019 [cited by applicant]
US 20190321414A1 · Lanza et al. · 2019 [cited by applicant]
US 20190358330A9 · Gay et al. · 2019 [cited by applicant]
US 20200023011A1 · Feng et al. · 2020 [cited by applicant]
US 20200113938A1 · Malcuit et al. · 2020 [cited by applicant]
US 20200405767A1 · Gay et al. · 2020 [cited by applicant]
US 20210102164A1 · Klimanskaya · 2021 [cited by applicant]
US 20210182552A1 · Kimbrel et al. · 2021 [cited by applicant]
US 20210308187A1 · Klimanskaya et al. · 2021 [cited by applicant]
US 20220160778A1 · Kimbrel et al. · 2022 [cited by applicant]
US 20220257663A1 · Lanza et al. · 2022 [cited by applicant]
US 20220347228A1 · Lanza et al. · 2022 [cited by applicant]
US 20230028239A1 · Feng et al. · 2023 [cited by applicant]
US 20240226176A9 · Klimanskaya et al. · 2024 [cited by applicant]
US 20240307436A2 · Malcuit et al. · 2024 [cited by applicant]
US 20240368541A1 · Abe et al. · 2024 [cited by applicant]
US 20240409892A1 · McCabe et al. · 2024 [cited by applicant]
CN 1102851C · 1996 [cited by applicant]
CN 103783031A · 2014 [cited by applicant]
EP 0562188A1 · 1993 [cited by applicant]
EP 0781547A1 · 1997 [cited by applicant]
EP 1067907B1 · 2001 [cited by applicant]
JP H09216826A · 1997 [cited by applicant]
JP 2011500024A · 2011 [cited by applicant]
KR 1020010023180A · 2001 [cited by applicant]
KR 20020063271A · 2002 [cited by applicant]
KR 1020090043559A · 2009 [cited by applicant]
WO WO9428950A1 · 1994 [cited by applicant]
WO WO2006080952A2 · 2006 [cited by applicant]
WO WO2007120811A2 · 2007 [cited by applicant]
WO WO2009051671A1 · 2009 [cited by applicant]
WO WO2009137624A2 · 2009 [cited by applicant]
WO WO2009137629A2 · 2009 [cited by applicant]
WO WO2011068896A1 · 2011 [cited by applicant]
WO WO2011069127A1 · 2011 [cited by applicant]
WO WO2014095953A1 · 2014 [cited by applicant]
WO WO2021041591A1 · 2021 [cited by applicant]
WO WO2021041592A1 · 2021 [cited by applicant]
WO WO2021086911A1 · 2021 [cited by applicant]
Hogan MJ. The preparation and sterilization of ophthalmic solutions. Calif Med. Dec. 1949;71(6):414-6. PMID: 15408108; PMCID: PMC1520227. (Year: 1949). [cited by examiner]
International Search Report and Written Opinion for Application No. PCT/US2016/047545 mailed Nov. 9, 2016. [cited by applicant]
International Preliminary Report on Patentability for Application No. PCT/US2016/047545 mailed Mar. 1, 2018. [cited by applicant]
Bureau of Drug Administration & Policy of Ministry of Health of the People's Republic of China, The Good Preparation Practice in The Chinese Hospital. Nov. 1989; 215-220. [cited by applicant]
Castanheira et al., Retinal incorporation and differentiation of mesenchymal stem cells intravitreally injected in the injured retina of rats. Arq Bras Oftalmol. Aug. 7, 2008;71(5):644-50. [cited by applicant]
Da Silva et al., Smart thermoresponsive coatings and surfaces for tissue engineering: switching cell-material boundaries. Trends Biotechnol. Dec. 2007;25(12):577-83. Epub Nov. 8, 2007. Review. Abstract. [cited by applicant]
Hsiue et al., A novel strategy for corneal endothelial reconstruction with a bioengineered cell sheet. Transplantation. Feb. 15, 2006;81(3):473-6. [cited by applicant]
Ide et al., Structural characterization of bioengineered human corneal endothelial cell sheets fabricated on temperature-responsive culture dishes. Biomaterials. Feb. 2006;27(4):607-14. Epub Aug. 15, 2005. Abstract. [cited by applicant]
Levkovitch-Verbin et al., Intravitreal Injections of Neurotrophic Factors Secreting Mesenchymal Stem Cells Are Neuroprotective in Rat Eyes following Optic Nerve Transection. IOVS. Dec. 2010;51(12):6394-6400. [cited by applicant]
Nishida et al., Corneal reconstruction with tissue-engineered cell sheets composed of autologous oral mucosal epithelium. N Engl J Med. Sep. 16, 2004;351(12):1187-96. [cited by applicant]
Nishida et al., Functional bioengineered corneal epithelial sheet grafts from corneal stem cells expanded ex vivo on a temperature-responsive cell culture surface. Transplantation. Feb. 15, 2004;77(3):379-85. [cited by applicant]
Renjun et al., The Treatment of Corneal Disease by Traditional Chinese Medicine and Western Medicine. Aug. 2004; 540-545. [cited by applicant]
Shouyi et al., Biosafety and The Prevention of Pollution. Jul. 2000; 201-205. [cited by applicant]
Sumide et al., Functional human corneal endothelial cell sheets harvested from temperature-responsive culture surfaces. FASEB J. Feb. 2006;20(2):392-4. Epub Dec. 9, 2005. [cited by applicant]
Wentang et al., Diseases of the Eye and Immunity. Chapter 17 in: Clinical Immunology. Jul. 2002; 291-296. [cited by applicant]
PCT/US2016/047545, Nov. 9, 2016, International Search Report and Written Opinion. [cited by applicant]
PCT/US2016/047545, Mar. 1, 2018, International Preliminary Report on Patentability. [cited by applicant]